{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T09:53:04Z","timestamp":1781517184121,"version":"3.54.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00210-026-05116-z","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T06:52:35Z","timestamp":1771397555000},"page":"11469-11481","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identifying cardiac safety signals of disproportionate reporting for CGRP antagonists: evidence from the FDA Adverse Event Reporting System"],"prefix":"10.1007","volume":"399","author":[{"given":"Shuaimin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"issue":"4","key":"5116_CR1","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3390\/cells11040654","volume":"11","author":"J Abd Alla","year":"2022","unstructured":"Abd Alla J, Quitterer U (2022) The RAF kinase inhibitor protein (RKIP): good as tumour suppressor, bad for the heart. Cells 11(4):654","journal-title":"Cells"},{"issue":"19","key":"5116_CR2","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1212\/WNL.0000000000201332","volume":"99","author":"J Ailani","year":"2022","unstructured":"Ailani J, Kaiser EA, Mathew PG, McAllister P, Russo AF, V\u00e9lez C et al (2022) Role of calcitonin gene-related peptide on the gastrointestinal symptoms of migraine-clinical considerations: a narrative review. Neurology 99(19):841\u2013853","journal-title":"Neurology"},{"key":"5116_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1204734","volume":"14","author":"MAM Al-Karagholi","year":"2023","unstructured":"Al-Karagholi MAM, Kalatharan V, Fagerberg PS, Amin FM (2023) The vascular role of CGRP: a systematic review of human studies. Front Neurol 14","journal-title":"Front Neurol"},{"issue":"1","key":"5116_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s10194-025-02180-3","volume":"26","author":"AP Andreou","year":"2025","unstructured":"Andreou AP, Hill B, Al-Rawi R, Murphy M, Soares I, Briscoe J et al (2025) A prospective real-world analysis of intravenous eptinezumab in migraine management: the first UK experience. J Headache Pain 26(1):235","journal-title":"J Headache Pain"},{"issue":"3","key":"5116_CR5","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40259-022-00530-0","volume":"36","author":"F Cohen","year":"2022","unstructured":"Cohen F, Yuan H, Silberstein SD (2022) Calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies and antagonists in migraine: current evidence and rationale. BioDrugs 36(3):341\u2013358","journal-title":"BioDrugs"},{"issue":"1","key":"5116_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/head.14827","volume":"65","author":"A de Dios","year":"2025","unstructured":"de Dios A, Pag\u00e8s-Puigdemont N, Ojeda S, Riera P, Pelegr\u00edn R, Morollon N et al (2025) Persistence, effectiveness, and tolerability of anti-calcitonin gene-related peptide monoclonal antibodies in patients with chronic migraine. Headache 65(1):24\u201334","journal-title":"Headache"},{"issue":"8","key":"5116_CR7","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1177\/03331024221076485","volume":"42","author":"HC Diener","year":"2022","unstructured":"Diener HC, McAllister P, J\u00fcrgens TP, Kessler Y, Ning X, Cohen JM et al (2022) Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies. Cephalalgia Int J Headache 42(8):769\u2013780","journal-title":"Cephalalgia Int J Headache"},{"issue":"8","key":"5116_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ et al (2021) Diagnosis and management of migraine in ten steps. Nat Rev Neurol 17(8):501\u2013514","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"5116_CR9","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213852","volume":"105","author":"MT Eller","year":"2025","unstructured":"Eller MT, Schwarzov\u00e1 K, Gufler L, Karisik A, Kaltseis K, Frank F et al (2025) CGRP-targeted migraine therapies in patients with vascular risk factors or stroke: a review. Neurology 105(2)","journal-title":"Neurology"},{"issue":"1","key":"5116_CR10","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s10194-024-01822-2","volume":"25","author":"M Hou","year":"2024","unstructured":"Hou M, Luo X, He S, Yang X, Zhang Q, Jin M et al (2024) Efficacy and safety of atogepant, a small molecule CGRP receptor antagonist, for the preventive treatment of migraine: a systematic review and meta-analysis. J Headache Pain 25(1):116","journal-title":"J Headache Pain"},{"issue":"5","key":"5116_CR11","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1016\/j.bja.2024.10.013","volume":"134","author":"H Huang","year":"2025","unstructured":"Huang H, Hu C, Liu F, Ji F, Fu Y, Cao M (2025) Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system. Br J Anaesth 134(5):1486\u20131496","journal-title":"Br J Anaesth"},{"issue":"1","key":"5116_CR12","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s42399-025-02059-z","volume":"7","author":"AV Krymchantowski","year":"2025","unstructured":"Krymchantowski AV, Krymchantowski AG, Pimentel MLV, Da Cunha JC, Cotrik EM (2025) A systematic review and meta-analysis of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) and gepants for episodic or chronic migraine with or without medication overuse headache. SN Compr Clin Med 7(1):321","journal-title":"SN Compr Clin Med"},{"issue":"6","key":"5116_CR13","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/head.14942","volume":"65","author":"AM Kuczynski","year":"2025","unstructured":"Kuczynski AM, Kingston WS (2025) Genetic migraine disorders and the response to calcitonin gene-related peptide antagonist treatment. Headache 65(6):1041\u20131043","journal-title":"Headache"},{"issue":"1","key":"5116_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/head.14234","volume":"62","author":"MJA L\u00e1inez","year":"2022","unstructured":"L\u00e1inez MJA, Schoenen J, Stroud C, Bardos J, Bangs M, Kemmer P et al (2022) Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment. Headache 62(1):65\u201377","journal-title":"Headache"},{"key":"5116_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2025.2497394","volume":"28","author":"N Lee","year":"2025","unstructured":"Lee N, Ok J, Kwon Y, Rhee SJ, Kim Y (2025) Identifying signals of disproportionate reporting for calcitoningene-related peptide inhibitors: real-world evidence from the FDA Adverse Event Reporting System.Expert Opin Drug Saf 28:1\u201310. https:\/\/doi.org\/10.1080\/14740338.2025.2497394","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"5116_CR16","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1038\/s41467-022-30868-6","volume":"13","author":"P Li","year":"2022","unstructured":"Li P, Liu B, Wu X, Lu Y, Qiu M, Shen Y et al (2022) Perirenal adipose afferent nerves sustain pathological high blood pressure in rats. Nat Commun 13(1):3130","journal-title":"Nat Commun"},{"key":"5116_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1431562","volume":"15","author":"Q Liang","year":"2024","unstructured":"Liang Q, Liao X, Wu H, Huang Y, Liang T, Li H (2024) Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. food and drug administration\u2019s adverse event reporting system databases. Front Pharmacol 15","journal-title":"Front Pharmacol"},{"issue":"359","key":"5116_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123177","volume":"15","author":"K Lin","year":"2024","unstructured":"Lin K, Stiles J, Tambo W, Ajmal E, Piao Q, Powell K et al (2024) Bimodal functions of calcitonin gene-related peptide in the brain. Life Sci 15(359)","journal-title":"Life Sci"},{"key":"5116_CR19","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.2147\/JPR.S453806","volume":"17","author":"RB Lipton","year":"2024","unstructured":"Lipton RB, Thiry A, Morris BA, Croop R (2024) Efficacy and safety of rimegepant 75 mg oral tablet, a CGRP receptor antagonist, for the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. J Pain Res 17:2431\u20132441","journal-title":"J Pain Res"},{"issue":"9","key":"5116_CR20","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.tips.2016.06.002","volume":"37","author":"A MaassenVanDenBrink","year":"2016","unstructured":"MaassenVanDenBrink A, Meijer J, Villal\u00f3n CM, Ferrari MD (2016) Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci 37(9):779\u2013788","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"5116_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s10194-024-01893-1","volume":"25","author":"A Maddahi","year":"2024","unstructured":"Maddahi A, Edvinsson JCA, Edvinsson L (2024) Sex differences in expression of CGRP family of receptors and ligands in the rat trigeminal system. J Headache Pain 25(1):193","journal-title":"J Headache Pain"},{"issue":"8","key":"5116_CR22","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/head.13601","volume":"59","author":"PG Mathew","year":"2019","unstructured":"Mathew PG, Klein BC (2019) Getting to the heart of the matter: migraine, triptans, DHE, ditans, CGRP antibodies, first\/second-generation gepants, and cardiovascular risk. Headache 59(8):1421\u20131426","journal-title":"Headache"},{"issue":"1","key":"5116_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s42399-023-01452-w","volume":"5","author":"DD Mitsikostas","year":"2023","unstructured":"Mitsikostas DD, Alexoudi A, Arvaniti C, Giannouli E, Kouremenos \u0395, Constantinidis TS et al (2023) Hellenic headache society recommendations for the use of monoclonal antibodies targeting the calcitonin gene-related peptide pathway for the prevention of migraine and cluster headache\u20142023 update. SN Compr Clin Med 5(1):118","journal-title":"SN Compr Clin Med"},{"issue":"1","key":"5116_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s10194-025-02239-1","volume":"27","author":"A Mu\u00f1oz-Vendrell","year":"2025","unstructured":"Mu\u00f1oz-Vendrell A, Campoy-D\u00edaz S, Val\u00edn-Villanueva P, Casas-Lim\u00f3n J, Fern\u00e1ndez-L\u00e1zaro I, Gonz\u00e1lez-Garc\u00eda N et al (2025) Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response. J Headache Pain 27(1):2","journal-title":"J Headache Pain"},{"issue":"5","key":"5116_CR25","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1007\/s00415-021-10930-x","volume":"269","author":"CYH Ng","year":"2022","unstructured":"Ng CYH, Tan BYQ, Teo YN, Teo YH, Syn NLX, Leow AST et al (2022) Myocardial infarction, stroke and cardiovascular mortality among migraine patients: a systematic review and meta-analysis. J Neurol 269(5):2346\u20132358","journal-title":"J Neurol"},{"issue":"1","key":"5116_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/head.13684","volume":"60","author":"TM Oakes","year":"2020","unstructured":"Oakes TM, Kovacs R, Rosen N, Doty E, Kemmer P, Aurora SK et al (2020) Evaluation of cardiovascular outcomes in adult patients with episodic or chronic migraine treated with galcanezumab: data from three phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. Headache 60(1):110\u201323","journal-title":"Headache"},{"issue":"5","key":"5116_CR27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1080\/17581869.2025.2494494","volume":"15","author":"L Pellesi","year":"2025","unstructured":"Pellesi L, Jedie B, Barhum F, Al-Abdullah S, Martelletti P, Xiao Z (2025) Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment. Pain Manag 15(5):279\u2013284","journal-title":"Pain Manag"},{"issue":"3","key":"5116_CR28","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/cpt.3701","volume":"118","author":"E Potter","year":"2025","unstructured":"Potter E, Reyes M, Naples J, Dal Pan G (2025) FDA adverse event reporting system (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS. Clin Pharmacol Ther 118(3):567\u2013582","journal-title":"Clin Pharmacol Ther"},{"key":"5116_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.910225","volume":"9","author":"TM Rhee","year":"2022","unstructured":"Rhee TM, Choi EK, Han KD, Ahn HJ, Lee SR, Oh S et al (2022) Type and severity of migraine determines risk of atrial fibrillation in women. Front Cardiovasc Med 9","journal-title":"Front Cardiovasc Med"},{"key":"5116_CR30","doi-asserted-by":"publisher","unstructured":"Rubio-Beltr\u00e1n E, van den Brink AM (2019) Understanding CGRP and Cardiovascular Risk. Handb Exp Pharmacol 255:131\u2013140. https:\/\/doi.org\/10.1007\/164_2019_204","DOI":"10.1007\/164_2019_204"},{"issue":"1","key":"5116_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R et al (2022) European headache federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain 23(1):67","journal-title":"J Headache Pain"},{"issue":"9","key":"5116_CR32","volume":"11","author":"A Saeed","year":"2019","unstructured":"Saeed A, Rana KF, Warriach ZI, Tariq MA, Malik BH (2019) Association of migraine and ischemic heart disease: a review. Cureus 11(9)","journal-title":"Cureus"},{"issue":"10","key":"5116_CR33","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","volume":"36","author":"O Sauzet","year":"2013","unstructured":"Sauzet O, Carvajal A, Escudero A, Molokhia M, Cornelius VR (2013) Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf 36(10):995\u20131006","journal-title":"Drug Saf"},{"issue":"11","key":"5116_CR34","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/S1474-4422(22)00294-0","volume":"21","author":"AS Schott Andersen","year":"2022","unstructured":"Schott Andersen AS, Maarbjerg S, Noory N, Heinskou TB, Forman JL, Cruccu G et al (2022) Safety and efficacy of erenumab in patients with trigeminal neuralgia in denmark: a double-blind, randomised, placebo-controlled, proof-of-concept study. Lancet Neurol 21(11):994\u20131003","journal-title":"Lancet Neurol"},{"issue":"3","key":"5116_CR35","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/ene.15198","volume":"29","author":"A Scutelnic","year":"2022","unstructured":"Scutelnic A, Mattle HP, Branca M, Jung S, Reichlin T, Fischer U et al (2022) Migraine and atrial fibrillation: A systematic review. Eur J Neurol 29(3):910\u2013920","journal-title":"Eur J Neurol"},{"issue":"2","key":"5116_CR36","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s12325-022-02346-4","volume":"40","author":"SD Silberstein","year":"2023","unstructured":"Silberstein SD, Reshef S, Cohen JM, Gandhi S, Seminerio M, Ramirez Campos V et al (2023) Adverse events reported with therapies targeting the CGRP pathway during the first 6 months post-launch: a retrospective analysis using the FDA adverse events reporting system. Adv Ther 40(2):445\u2013459","journal-title":"Adv Ther"},{"issue":"1","key":"5116_CR37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s10194-025-02091-3","volume":"26","author":"Q Song","year":"2025","unstructured":"Song Q, Gao S, Tan Y (2025) Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System. J Headache Pain 26(1):147","journal-title":"J Headache Pain"},{"issue":"2","key":"5116_CR38","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40259-024-00651-8","volume":"38","author":"EE Sorbara","year":"2024","unstructured":"Sorbara EE, Barbieri MA, Russo G, Cicala G, Spina E (2024) Cardiovascular adverse drug reactions of anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: an analysis from the European spontaneous adverse event reporting system. BioDrugs 38(2):275\u2013285","journal-title":"BioDrugs"},{"key":"5116_CR39","doi-asserted-by":"crossref","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z (2020) Lifting The Burden: the Global Campaign against Headache. Migraine remains second among the world\u2019s causes of disability, and first among young women: Findings from GBD2019. J Headache Pain 21(1):137","DOI":"10.1186\/s10194-020-01208-0"},{"issue":"1","key":"5116_CR40","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s10194-025-02040-0","volume":"26","author":"M Straburzy\u0144ski","year":"2025","unstructured":"Straburzy\u0144ski M, Kopyt D, Marschollek K, B\u0142aszczyk B, Kuca-Warnawin E, Kurowska W et al (2025) Increased infection risk in patients on preventive CGRP-targeting therapies- a meta-analysis and clinical effect assessment. J Headache Pain 26(1):88","journal-title":"J Headache Pain"},{"key":"5116_CR41","doi-asserted-by":"publisher","first-page":"1257282","DOI":"10.3389\/fphar.2023.1257282","volume":"14","author":"W Sun","year":"2023","unstructured":"Sun W, Li Y, Xia B, Chen J, Liu Y, Pang J et al (2023) Adverse event reporting of four anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA Adverse Event Reporting System. Front Pharmacol 14:1257282","journal-title":"Front Pharmacol"},{"issue":"7","key":"5116_CR42","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s11916-022-01056-4","volume":"26","author":"YF Wang","year":"2022","unstructured":"Wang YF, Wang SJ (2022) CGRP targeting therapy for chronic migraine-evidence from clinical trials and real-world studies. Curr Pain Headache Rep 26(7):543\u2013554","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"5116_CR43","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1080\/10717544.2021.1902021","volume":"28","author":"F Wang","year":"2021","unstructured":"Wang F, Deng Y, Wang J, Yu L, Ding F, Lian W et al (2021) The PLGA nanoparticles for sustainable release of CGRP to ameliorate the inflammatory and vascular disorders in the lung of CGRP-deficient rats. Drug Deliv 28(1):865\u2013872","journal-title":"Drug Deliv"},{"issue":"1","key":"5116_CR44","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s10194-023-01640-y","volume":"24","author":"K Wang","year":"2023","unstructured":"Wang K, Fenton BT, Dao VX, Guirguis AB, Anthony SE, Skanderson M et al (2023) Trajectory of blood pressure after initiating anti-calcitonin gene-related peptide treatment of migraine: a target trial emulation from the Veterans Health Administration. J Headache Pain 24(1):108","journal-title":"J Headache Pain"},{"issue":"1","key":"5116_CR45","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/14740338.2023.2250720","volume":"23","author":"Q Wang","year":"2024","unstructured":"Wang Q, Liu J, Sun H, Dong Y, Tan W, Tang Z et al (2024) Adverse event profile of CGRP monoclonal antibodies: findings from the FDA adverse event reporting database. Expert Opin Drug Saf 23(1):107\u2013117","journal-title":"Expert Opin Drug Saf"},{"key":"5116_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103385","volume":"86","author":"M Wang","year":"2025","unstructured":"Wang M, Chen X, Liu Z, Li Z, Zhu Z, Liu S et al (2025) Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data. EClinicalMedicine 86","journal-title":"EClinicalMedicine"},{"issue":"11","key":"5116_CR47","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1080\/14737175.2024.2401558","volume":"24","author":"WD Wells-Gatnik","year":"2024","unstructured":"Wells-Gatnik WD, Pellesi L, Martelletti P (2024) Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine. Expert Rev Neurother 24(11):1107\u20131117","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"5116_CR48","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1001\/jamaneurol.2024.4537","volume":"82","author":"S Yang","year":"2025","unstructured":"Yang S, Orlova Y, Park H, Smith SM, Guo Y, Chapin BA et al (2025) Cardiovascular safety of anti-CGRP monoclonal antibodies in older adults or adults with disability with migraine. JAMA Neurol 82(2):132\u2013141","journal-title":"JAMA Neurol"},{"key":"5116_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1397692","volume":"15","author":"M Yu","year":"2024","unstructured":"Yu M, Zhou L, Cao M, Ji C, Zheng Y (2024) Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database. Front Immunol 15","journal-title":"Front Immunol"},{"issue":"1","key":"5116_CR50","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s10194-025-01984-7","volume":"26","author":"Z Zhu","year":"2025","unstructured":"Zhu Z, Tang Y, Li L, Ni H, Liu M, Chen Z et al (2025) The efficacy and safety of zavegepant nasal inhalation versus oral calcitonin-gene related peptide receptor antagonists in the acute treatment of migraine: a systematic review and network meta-analysis of the literature. J Headache Pain 26(1):48","journal-title":"J Headache Pain"},{"key":"5116_CR51","doi-asserted-by":"publisher","unstructured":"Zhuang S, Wang B, Wu E et al (2025) Adverse cardiac events associated with antibody-drug conjugates incancer patients: retrospective analysis of FAERS database and RCTs. Cardiovasc Res 121(15):2318\u20132333. https:\/\/doi.org\/10.1093\/cvr\/cvaf095","DOI":"10.1093\/cvr\/cvaf095"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05116-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05116-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05116-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T09:04:33Z","timestamp":1781514273000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05116-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5116"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05116-z","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data of this study is available publicly. Therefore, permission is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}